Incyte | INCY - Pre Tax Profit

Stock Price
108.39
Daily Change
5.63 5.48%
Monthly
-1.97%
Yearly
46.22%
Q1 Forecast
96.99

Incyte reported $482.31M in Pre-Tax Profit for its fiscal quarter ending in September of 2025.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 44.6M 4.38M Sep/2025
Agios Pharmaceuticals USD -103.43M 8.59M Sep/2025
Alnylam Pharmaceuticals USD 238.97M 274.33M Sep/2025
Amgen USD 3.92B 2.35B Sep/2025
Biogen USD 557.3M 186.7M Sep/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Eli Lilly USD 7.23B 456M Sep/2025
Exelixis USD 252.41M 22M Sep/2025
Gilead Sciences USD 2.43B 780M Jun/2025
Incyte USD 482.31M 75.7M Sep/2025
Ionis Pharmaceuticals USD -129M 253M Sep/2025
MacroGenics USD 16.82M 52.97M Sep/2025
Merck USD 6.74B 22M Sep/2025
Moderna USD -187M 631M Sep/2025
Neurocrine Biosciences USD 291.8M 132.3M Sep/2025
Novartis USD 4.2B 335M Sep/2025
Novartis USD 5.17B 637M Sep/2025
Pfizer USD 3.33B 290M Sep/2025
PTC Therapeutics USD -23.07M 47.98M Sep/2025
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Sarepta Therapeutics USD -194.05M 347.69M Sep/2025
Ultragenyx Pharmaceutical USD -179.54M 65.54M Sep/2025
Vertex Pharmaceuticals USD 1.3B 15.8M Sep/2025